Please login to the form below

Not currently logged in
Email:
Password:

Akcea

This page shows the latest Akcea news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Akcea’s rare inherited disorder drug Waylivra

NICE rejects Akcea’s rare inherited disorder drug Waylivra

Akcea’s drug was handed conditional approval by the European Medicines Agency (EMA) last  May, making Europe its first market. ... Waylivra was Akcea’s second drug to reach the market last year after transthyretin-related amyloidosis (ATTR)

Latest news

More from news
Approximately 10 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Standing in its way is a similarly priced antisense rival from Ionis and Akcea – Tegsedi (inotersen) – as well as Pfizer’s fast- growing Vyndaqel/Vyndamax (tafamidis), which is approved for hATTR

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    two entering the field at the same time. So it is with Alnlyam: Ionis and Akcea secured EMA approval in July for their antisense candidate Tegsedi (inotersen), while Pfizer has just

  • Deal Watch January 2017 Deal Watch January 2017

    As you sow, so shall you reap The use of options is remaining widespread as noted in the Novartis deal with Ionis and Akcea. ... 1, 700. Ionis | Akcea. Novartis. Exclusive option to licence. AKCEA-APOCIII-LRx for heart failure.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics